Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831493 · ClinicalTrials.gov registry record · Phase 1
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00831493: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00831493 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831493, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1. To assess the efficacy of vorinostat + RT in patients with LAPC as estimated by median overall survival. 2. To determine the radiological response as assessed by regular computer tomography (CT) and/or dynamic contrast enhanced computer tomography (DCE-CT) among patients treated with vorinostat and RT. 3. To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Gastrointestinal Module (MDASI-GI) self-reporting tool. 4. To correlate serum cytokine levels with symptoms and treatment outcomes.
Interventions
- DRUG Vorinostat
- RADIATION Chemoradiation (Radiation Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831493
The ClinicalTrials.gov registry entry for NCT00831493 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT00831493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831493 about?
NCT00831493 is a clinical study titled "Vorinostat Plus Radiation Therapy in Pancreatic Cancer". Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1. To assess the efficacy of vorinostat + RT in patients with LAPC as estimated by median overall survival. 2. To...
What is the current status of trial NCT00831493?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-05. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00831493?
The interventions under investigation include: Vorinostat (DRUG), Chemoradiation (Radiation Therapy) (RADIATION).
Who is sponsoring clinical trial NCT00831493?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.